Tripartite motif 16 suppresses breast cancer stem cell properties through regulation of Gli-1 degradation via the ubiquitin-proteasome pathway

JUNTAO YAO1, TAO XU2, TAO TIAN3, XIAO FU3, WENJUAN WANG3, SUONI LI4, TINGTING SHI3, ALI SUO3, ZHIPING RUAN3, HUI GUO3 and YU YAO3

1The Integrated Department of TCM and Western Medicine, Shaanxi Provincial Tumor Hospital; 2Department of Thoracic Surgery, The Center Hospital of Xi'an; 3Department of Oncology, The First Affiliated Hospital of Xi’an Jiaotong University; 4Department of Oncology, Shaanxi Provincial Tumor Hospital, Xi'an, Shaanxi 710061, P.R. China

Received August 31, 2015; Accepted October 23, 2015

DOI: 10.3892/or.2015.4437

Abstract. Cancer stem cells (CSCs) are responsible for cancer progression and patient prognosis. Tripartite motif 16 (TRIM16) is a proteasome coactivator that regulates proteolytic activity in eukaryotic cells. Abundant evidence has shown that TRIM16 is lowly expressed in a number of human carcinomas. In a previous study, we demonstrated that TRIM16 suppressed cancer malignancy and that TRIM16 expression levels were associated with favorable prognostic parameters of patients with cancer. However, the precise role of this motif in the pathogenesis of breast cancer remains unknown. In the present study, we examined 29 human breast cancer specimens, and found that TRIM16 was lowly expressed in breast cancers; thus, TRIM16 expression is negatively correlated with metastasis in breast cancer patients. Moreover, we showed that TRIM16 suppressed CSC properties in a population of breast cancer cells. TRIM16 depletion resulted in an increased proportion of CSCs relative to breast cancer cells when several assays were used to assess CSC properties. Finally, we demonstrated that TRIM16 directly regulated the degradation of Gli-1 protein via the ubiquitin-proteasome pathway. In conclusion, we propose that inhibition of CSC properties may be one of the functions of TRIM16 as a suppressor of breast cancer progression.

Introduction

A growing number of solid tumors, including breast cancer, have been shown to contain a subpopulation of cells possessing tumor-initiating capability associated with stem cell properties that include expression of embryonic stem cell genes and asymmetric division (1). These cells, termed cancer stem cells (CSCs), are generally believed to represent the tumor repopulating force, preserving their own numbers through self-renewal, and generating more differentiated progeny that compose the bulk of the tumor (2). Thus, understanding the biology of CSCs would contribute to the development of novel breast cancer therapies by overcoming problems encountered.

In a previous study we showed that ubiquitin E3 ligase tripartite motif 16 (TRIM16) suppressed lung cancer malignancy (3). TRIM16 is also associated with many different types of cancers (4,5). Previous studies have identified TRIM16 as a DNA binding protein with histone acetyltransferase activity, which is necessary for the retinoic acid receptor β2 transcriptional response in retinoid-treated cancer cells (4). Overexpressed TRIM16 reduced neuroblastoma cell growth, enhanced retinoid-induced differentiation and decreased tumorigenicity in vivo (4). Moreover, TRIM16 was found to participate in several biological processes through ubiquitination of specific target proteins (5).

In our previous study, we found that TRIM16 expression levels were negatively correlated with tumor malignancy in human lung cancer tissues and significantly inhibited EMT and metastasis of lung cancer cells (3). In addition, a recent clinical study reported that TRIM16 expression levels were associated with favorable prognostic parameters of patients with breast cancer (6). Thus, TRIM16 may be a novel target for breast cancer therapy. However, many issues remain to be addressed regarding the mechanisms of how TRIM16 is involved in breast cancer progression.

In the present study, we demonstrated that TRIM16 was lowly expressed in breast cancers, and the expression of TRIM16 was negatively correlated with metastasis in breast cancer patients. Moreover, we showed that TRIM16 suppressed CSC properties in a population of breast cancer cells. We demonstrated that TRIM16 directly regulated the degradation of Gli-1 protein via the ubiquitin-proteasome pathway. Thus, TRIM16 may contribute to a favorable prognosis for patients with breast cancer through its inhibition of CSC properties.

Correspondence to: Professor Yu Yao, Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
E-mail: yaoyushanxi@sina.com

Key words: TRIM16, cancer stem cell, breast cancer, metastasis
Materials and methods

Chemicals and antibodies. Lipofectamine 2000 transfection and TRIzol LS reagents were purchased from Invitrogen (Grand Island, NY, USA). Antibodies against TRIM16 and Gli-1 were purchased from Abcam (Cambridge, MA, USA). HA, Myc, Flag and β-actin antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-CD24-PE and CD44-APC antibodies were from BD Biosciences (Franklin Lakes, NJ, USA). MG132 and cycloheximide (CHX) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Unless otherwise noted, all other chemicals were from Sigma-Aldrich.

Patients and specimens. Human normal breast tissues and breast cancer tissue samples were obtained from patients who underwent surgical therapeutic procedures at the Department of General Surgery, the First Affiliated Hospital of Xi’an Jiaotong University. All experiments were approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University, and informed consent was obtained from all patients prior to specimen collection. The clinical and pathological information of the breast cancer patients are provided in Table I.

Cell culture. Breast cancer cell lines (ATCC, Manassas, VA, USA) were cultured under the following conditions. BT-20, MDA-MB-468, BT549, MDA-MB-231, and BT474 cell lines were cultured using 10% fetal bovine serum (cat no. 10099-141, Invitrogen, Carlsbad, CA, USA) in RPMI-1640 (cat no. C11875, Invitrogen). HCC1954, HCC1806, SK-bR-3, AU565 and T47D cell lines were cultured using 10% fetal bovine serum in Dulbecco’s modified Eagle’s medium (DMEM) (cat no. C11965, Invitrogen). Cell culture medium was carried out according to the manufacturer’s protocol. All the cell lines were grown at 37˚C in a 5% CO₂/95% air atmosphere and were revived every 3-4 months.

Establishment of TRIM16 stable expression and knock-down cell lines. A retroviral construct containing human pBabe-TRIM16 cDNA, and pSuper-retro-puro with shRNA against human TRIM16 were prepared as described previously (7). The generation of retroviral supernatants and transfection of breast cancer cells were conducted as described previously (7). The expression of TRIM16 was confirmed by western blotting.

Gli-1-specific shRNA inhibition. To knock down Gli-1 expression, shRNA targeting Gli-1 expressed in the pSingle vector was prepared as described previously (8). Cells were grown in dishes until they reached 75% confluency, at which point they were transfected for 24 h with pSingle-shRNA specific to Gli-1 using Lipofectamine 2000 transfection reagent according to the manufacturer’s instructions. The tight on/off regulation of the pSingle vector system and coordinate inactivation of the target gene are mediated by doxycycline (Dox). Expression of the shRNA in the absence of induction is extremely low and prevents unwanted suppression of the target gene. When Dox is added to the culture medium, transcriptional suppression is relieved, permitting the shRNA to be transcribed.

Table I. Association between TRIM16 expression and clinicopathological factors in the 29 breast cancer patients.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>TRIM16 negative n (%)</th>
<th>TRIM16 positive n (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;35</td>
<td>3 (17)</td>
<td>11 (83)</td>
<td>0.537</td>
</tr>
<tr>
<td>≥35</td>
<td>2 (19)</td>
<td>13 (81)</td>
<td></td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2</td>
<td>14 (84)</td>
<td>2 (16)</td>
<td>0.0001*</td>
</tr>
<tr>
<td>&gt;2</td>
<td>7 (43)</td>
<td>6 (57)</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>11 (58)</td>
<td>8 (42)</td>
<td>0.006*</td>
</tr>
<tr>
<td>Positive</td>
<td>3 (30)</td>
<td>7 (70)</td>
<td></td>
</tr>
<tr>
<td>Histological grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1, 2</td>
<td>4 (14)</td>
<td>8 (86)</td>
<td>0.522</td>
</tr>
<tr>
<td>3</td>
<td>1 (9)</td>
<td>14 (91)</td>
<td></td>
</tr>
<tr>
<td>Estrogen receptor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>5 (35)</td>
<td>12 (65)</td>
<td>0.489</td>
</tr>
<tr>
<td>Positive</td>
<td>2 (26)</td>
<td>10 (74)</td>
<td></td>
</tr>
<tr>
<td>Progesterone receptor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>3 (27)</td>
<td>13 (73)</td>
<td>0.471</td>
</tr>
<tr>
<td>Positive</td>
<td>4 (31)</td>
<td>9 (69)</td>
<td></td>
</tr>
<tr>
<td>Her-2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>5 (18)</td>
<td>17 (82)</td>
<td>0.642</td>
</tr>
<tr>
<td>Positive</td>
<td>1 (9)</td>
<td>6 (91)</td>
<td></td>
</tr>
</tbody>
</table>

*Significant difference.

After transfection, the cells were trypsinized, collected and subjected to various experiments.

Western blotting. Cells were lysed in lysis buffer, and total protein contents were determined by the Bradford method. A total of 30 µg of lysis was separated by reducing SDS-PAGE and probed with specific antibodies. Blots were washed and probed with respective secondary peroxidase-conjugated antibodies, and the bands were visualized by chemoluminescence (Amersham Biosciences GmbH, Freiburg, Germany).

qRT-PCR. Total RNA was extracted using TRIzol reagent and cDNA was synthesized using SuperScript II Reverse Transcriptase (Invitrogen). qRT-PCR and data collection were performed with an ABI PRISM 7900HT sequence detection system. The primers used for the amplification of the indicated genes are available upon request.

Sphere forming assay. Mammosphere culture was performed as described previously (9) with slight modifications. Single-cell suspensions were plated in ultralow attachment 96-well plates (Costar, Cambridge, MA, USA) at different densities of viable cells. Cell were grown in a serum-free mammary epithelial growth medium (MEGM), supplemented with 1:50 B27 (Invitrogen), 20 ng/ml epithelial growth factor, 100 ng/ml basic fibroblast growth factor, 50 ng/ml insulin, and 10 ng/ml epidermal growth factor.
factor (EGF), 20 ng/ml basic fibroblast growth factor (bFGF; BD Biosciences) and 10 µg/ml heparin (Sigma-Aldrich). The numbers of spheroids were counted after 7-10 days.

Fluorescence-activated cell sorting (FACS) analysis. Anti-CD44-APC and anti-CD24-PE antibodies used for FACS analysis were obtained from Biolegend (San Diego, CA, USA). Briefly, for each cell line, 1x10^6 cells were aliquotted into two tubes; tube 1 was stained with IgG isotype controls for APC and PE, and tube 2 was stained with anti-CD44-APC and anti-CD24-PE. Cells were incubated with the appropriate antibodies for 30 min on ice and then washed with PBS. Cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences); each sample required 10,000 cells for analysis.

Gli-1 half-life chase and Gli-1-ubiquitin co-immunoprecipitation. For Gli-1 half-life chase, the cells were treated with 40 µg/ml cycloheximide (CHX) before harvesting. Proteasome inhibitor MG132 was used to eliminate proteasome degradation of Gli-1. For Gli-1-ubiquitin co-immunoprecipitation assay, the cells were firstly transfected with the exogenous expression plasmid carrying FLAG-tagged Gli-1, Myc-tagged TRIM16 and HA-tagged ubiquitin. After transfection, the cells were incubated with 10 mM MG132 or vehicle reagent DMSO 6 h before harvesting. Gli-1 was precipitated using an anti-FLAG antibody at a 1:500 dilution, and the ubiquitinylation degradation of ERα was detected by the anti-HA antibody at a 1:500 dilution.

Statistical analysis. The results were analyzed using SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA). Each experiment was repeated a minimum of three times. A two-tailed t-test was used to determine statistical significance. The results were presented as the means ± SD. P<0.05 was considered to indicate a statistically significant difference.

Results

Expression of TRIM16 is downregulated in breast cancer tissues. We previously demonstrated that the expression of TRIM16 was markedly decreased in lung cancer and correlated with lung cancer metastasis (3). These findings suggested that TRIM16 may function as a tumor suppressor in breast cancer. To test this hypothesis, we first compared the expression levels of TRIM16 in 29 breast cancer tissue samples to those in the adjacent normal tissues using qRT-PCR (Fig. 1A) and western blotting (Fig. 2A). Both the expression of TRIM16 at the mRNA and protein levels were found to be reduced in the tumor lesions compared with the matched normal tissue lesions in almost all of the samples (Figs. 1B and 2B). In addition, we also found that TRIM16 expression was significantly correlated with distant metastasis in the breast cancer tissues (Figs. 1C and 2C). Consistent with this clinical observation, TRIM16 expression levels in non-invasive human breast cancer cell lines (BT-20, MDA-MB-468, BT474, HCC1954 and HCC1806) were much higher than the levels in invasive human breast cancer cell lines (BT549, MDA-MB-231, SK-BR-3, AU565 and T47D) (Fig. 3). These results suggest that
TRIM16 may play an important part in the development or progression of breast cancer.

Establishment of stable TRIM16 transfectants in breast cancer cells. We used shRNA to generate stable TRIM16-knockdown MDA-MB-468 and BT474 cell lines with the aim of revealing the role that TRIM16 expression has in the development or progression of breast cancer. We also used BT549 and AU565 cell lines to establish stable cell lines that constitutively overexpressed the TRIM16 protein. The transfection efficiency was confirmed using western blotting. As shown in Fig. 4A, the MDA-MB-468 and BT474 cells that had been transfected with the TRIM16 shRNA plasmid displayed significantly decreased TRIM16 expression at the protein levels compared with the control cells. In addition, the BT549 and AU565 cells that had been transfected with the TRIM16 expression plasmid displayed significantly increased TRIM16 expression at the protein level compared with the vector cell lines (Fig. 4B).

TRIM16 inhibits the emergence of cancer stem cell-like behavior in the breast cancer cell lines. In a previous study, we found that TRIM16 plays an important role in regulating EMT of lung cancer cells (3). Increasing evidence has linked EMT with acquisition of molecular and functional traits of stem cells in normal and neoplastic cell populations (10-12). Consistent with this concept, we first performed sphere formation

Figure 2. Expression of TRIM16 protein is downregulated in breast cancer tissues. (A) TRIM16 protein expression was analyzed by western blotting in 29 breast tumors and adjacent tissues. (B) Comparison of the expression levels of TRIM16 protein in breast tumors and adjacent tissues. (C) Comparison of the expression levels of TRIM16 protein in non-metastatic and metastatic breast cancer tissues. *P<0.01 is based on the Student’s t-test. All results are from three independent experiments. Error bars, SD.

Figure 3. Expression level of TRIM16 protein as assessed by western blotting in breast cancer cell lines. (A) Expression level of TRIM16 protein was assessed by western blotting in non-invasive human breast cancer cell lines (BT-20, MDA-MB-468, BT474, HCC1954 and HCC1806) and invasive human breast cancer cell lines (BT549, MDA-MB-231, SK-BR-3, AU565 and T47D). (B) Comparison of the relative expression levels of TRIM16 protein between non-invasive and invasive human breast cancer cell lines. *P<0.01 is based on the Student’s t-test. All results are from three independent experiments. Error bars, SD.
assays, to determine whether TRIM16 regulates certain stem cell-associated properties. When TRIM16 expression levels were reduced using shRNA for TRIM16 (shTRIM16) in the MDA-MB-468 and BT474 cells, sphere formation assay results showed that shTRIM16 cells more frequently formed spheres than did the shCtrl cells both for MDA-MB-468 (Fig. 4C) and BT474 (Fig. 4D) cell lines. By contrast, ectopic expression of TRIM16 in both the BT549 (Fig. 4E) and AU565 (Fig. 4F) cell lines significantly inhibited sphere-forming capability. Taken together, these results revealed that the TRIM16 expression level is negatively correlated with sphere-forming capability, which suggests that TRIM16 suppresses CSC phenotypes.

The CD44+/CD24- cell assay is one method used to assess breast CSC enrichment (13). We next analyzed the proportion of the CD44+/CD24- fraction in shTRIM16 or ectopic TRIM16 cells to further assess whether TRIM16 suppresses CSC phenotypes. The results showed that the proportion of the CD44+/CD24- cells in the shTRIM16 cells was markedly higher than that in the shCtrl cells (Fig. 5A and B). At the same time, ectopic TRIM16 in the BT549 and AU565 cells significantly decreased the proportion of CD44+/CD24- cells (Fig. 5C and D). This showed that TRIM16 depletion increases the CD44+/CD24- cells in breast cancer cells.

**TRIM16 regulates Gli-1 expression through degradation.** Previous, we demonstrated that downregulation of TRIM16 activated the sonic hedgehog (SHH) pathway in lung cancer cells (3), and Gli-1 is a key molecule in the SHH pathway. But whether TRIM16 regulates Gli-1 in breast cancer remains unknown. In the present study, we first assayed the expression of Gli-1 in shTRIM16 or ectopic TRIM16 cells. The results showed that the Gli-1 protein expression levels were significantly increased by TRIM16 knockdown in the MDA-MB-468 cells and significantly decreased by TRIM16 ectopic expression in the BT549 cells (Fig. 6A). Gli-1 mRNA level had no significant change in both the TRIM16-knockdown and ectopic expressing cells (Fig. 6B), indicating that the regulatory function of TRIM16 on Gli-1 expression occurs only at the post transcriptional level. Then, we investigated the time course for the effect of TRIM16 on Gli-1 expression by...
Figure 5. TRIM16 inhibits the emergence of cancer stem cell subpopulations in the breast cancer cell lines. (A) MDA-Mb-468-shTRIM16 and its control cells were stained with anti-CD44-APC and anti-CD24-PE antibodies, and the CD44+/CD24- subpopulations were examined by flow cytometry. (B) BT474-shTRIM16 and its control cells were stained with anti-CD44-APC and anti-CD24-PE antibodies, and the CD44+/CD24- subpopulations were examined by flow cytometry. (C) BT549-TRIM16 and its control cells were stained with anti-CD44-APC and anti-CD24-PE antibodies, and CD44+/CD24- subpopulations were examined by flow cytometry. (D) AU565-TRIM16 and its control cells were stained with anti-CD44-APC and anti-CD24-PE antibodies, and the CD44+/CD24- subpopulations were examined by flow cytometry. **P<0.01 is based on the Student's t-test. All results are from three independent experiments. Error bars, SD.

Figure 6. TRIM16 inhibits Gli-1 expression. (A) The levels of Gli-1 protein were assessed by western blotting in the MDA-Mb-468-shTRIM16, BT549-TRIM16 and their control cells. (B) The levels of Gli-1 mRNA were assessed by qRT-PCR in the MDA-Mb-468-shTRIM16, BT549-TRIM16 and their control cells. (C) Gli-1 protein half-life time chase data showing that Gli-1 degraded slowly by TRIM16 shRNA treatment in the MDA-Mb-468 cell line compared with the control cells. (D) Gli-1 protein half-life time chase data showing that Gli-1 degraded more quickly in the TRIM16 ectopic expressing BT549 cells, compared with the control cells.
examining the Gli-1 levels at different time points (0, 1, 2, 4 and 8 h) during TRIM16 knockdown or induction of ectopic expression. We found that Gli-1 protein degraded slowly in the shTRIM16-treated MDA-Mb-468 cells, compared with shCtrl-treated cells (Fig. 6C). In contrast, the Gli-1 protein degraded more quickly in the TRIM16 ectopic bT549 cells, compared with the Ctrl cells (Fig. 6D).

Next, in order to investigate whether the regulation of TRIM16 on Gli-1 protein is dependent on the ubiquin-proteasome pathway, we used a combined treatment of proteasome inhibitor MG132 with ectopic TRIM16 treatment. We found that Gli-1 degradation caused by TRIM16 ectopic expression was completely abrogated by proteasome inhibition (Fig. 7A and B), demonstrating that the regulation of Gli-1 expression by TRIM16 is indeed mediated via the proteasome-dependent pathway. Finally, we performed Gli-1-ubiquitin co-immunoprecipitation to shown that Gli-1 protein was more heavily ubiquitinated upon TRIM16 ectopic expression, compared with Ctrl treatment (Fig. 7C), confirming that the ubiquitin-proteasome pathway mediates the regulation of Gli-1 expression by TRIM16.

To determine whether there were any correlations between TRIM16 and Gli-1 in breast cancer specimens, we used 29 breast cancer samples to analyze the expression of Gli-1 by western blotting. We found that Gli-1 protein expression was negatively correlated with the TRIM16 protein expression level in the breast cancer specimens (Fig. 7D).

Gli-1 is a mediator for shTRIM16-induced cancer stem cell-like behavior in breast cancer cells. On the basis of the indispensable role of Gli-1 in the biologic functions of TRIM16, we silenced Gli-1 in the MDA-MB-468-shTRIM16 and BT474-shTRIM16 cells (Fig. 8A). Of note, Gli-1 silencing significantly decreased the sphere-forming capability of MDA-MB-468-shTRIM16 and BT474-shTRIM16 cells (Fig. 8B and C), and reversed shTRIM16-induced changes in the proportion of the CD44+/CD24- cells (Fig. 9A and B). Taken together, these results show that Gli-1 partly mediates shTRIM16-induced cancer stem cell-like behavior in breast cancer cells.

Discussion

A relatively new hypothesis of cancer progression indicates that CSCs mediate the progression of solid tumors, including breast cancer initiation and progression (14). This theory suggests that CSCs are only a minor subpopulation of cells (generally <1%) within the tumor that self-renew and give rise to differentiated tumor cells; most tumor cells are highly differentiated, have limited proliferative potential and are
non-tumorigenic (15). Several markers to identify prostate CSCs are available. Hence, clarifying the mechanisms of CSC regulation will greatly benefit our understanding of breast cancer metastasis. In the present study, we identified TRIM16 as a candidate target gene for the inhibition of breast CSCs.

The tripartite motif or TRIM is a family of proteins characterized by its multi-domain design consisting of three structurally distinct motifs: the RING finger zinc-binding domain, a B-box zinc-binding domain, and a coiled-coil domain (16). TRIM16 is also known as an estrogen-responsive B-box protein because of its original discovery as an estrogen-responsive protein in human mammary epithelial cells (17). TRIM16 has been shown to suppress tumor progression through regulatory pathways involving growth inhibition, migration, differentiation and apoptosis (18). Recent research has demonstrated that TRIM16 can heterodimerize with other TRIM proteins and exhibits E3 ubiquitin ligase activity (16). These data strongly support the supposition that TRIM16 is a tumor-suppressor gene. However, the exact mechanisms of TRIM16 in breast cancer remain unclear.

Tumor-suppressor genes can inhibit tumor invasion and metastatic potential. Loss of tumor-suppressor genes may lead to a malignant cancer phenotype (4). To confirm the tumor-suppressor function of TRIM16, we first examined the levels of TRIM16 in breast cancer samples and normal breast tissue samples. We found that TRIM16 was significantly

Figure 8. Gli-1 is a mediator for shTRIM16-induced cancer stem cell-like behavior in breast cancer cells. (A) The level of Gli-1 protein was verified by western blotting in the MDA-MB-468-shTRIM16-shGli-1, BT474-shTRIM16-shGli-1 and their control cells. (B) Sphere-forming capability of MDA-MB-468-shTRIM16-shCtrl and -shGli-1 cells was assayed by sphere formation. (C) Sphere-forming capability of BT474-shTRIM16-shCtrl and -shGli-1 cells was assayed by sphere formation. Representative photomicrographs (left panels) and numbers of spheres (right graphs) are shown. "P<0.01 is based on the Student's t-test. All results are from three independent experiments. Error bars, SD.

Figure 9. Gli-1 is a mediator of the shTRIM16-induced change in the cancer stem cell subpopulation increase in breast cancer cells. (A) MDA-MB-468-shTRIM16-shGli-1 and its control cells were stained with anti-CD44-APC and anti-CD24-PE antibodies, and CD44+/CD24- subpopulations were examined by flow cytometry. (B) BT474-shTRIM16-shGli-1 and its control cells were stained with anti-CD44-APC and anti-CD24-PE antibodies, and CD44+/CD24- subpopulations were examined by flow cytometry. "P<0.01 is based on the Student's t-test. All results are from three independent experiments. Error bars, SD.
reduced in breast cancers, which suggests that TRIM16 is a candidate tumor-suppressor gene in breast cancer. ShiTrim16 cells more frequently formed spheres than did shCtrl cells. By contrast, ectopic expression of TRIM16 significantly inhibited sphere-forming capability. We further found that TRIM16 depletion increased the number of CD44+/CD24- cells relative to that of breast cancer cells. These results indicate that TRIM16 expression levels are negatively correlated with sphere-forming capability, and suggest that TRIM16 suppresses a number of CSC phenotypes.

The SHH pathway in mammalian cells is mediated by ligands SHH (19). Gli-1 is a strong positive activator of downstream target genes and is itself a transcriptional target of the SHH pathway. Therefore, Gli-1 is considered a marker of abnormal activation of the SHH pathway (20). Gli-1 plays a critical role in many CSCs, such as glioblastoma stem cells, CD34+ leukemic cells, and breast CSCs (21) and it promotes CSC self-renewal in cancer cell lines by inducing Snail expression (21). In the present study, we found that the ubiquitin-proteasome pathway mediated the regulation of Gli-1 expression by TRIM16 in breast cancer cells, consistent with our previous results as well as those of others. We also determined that Gli-1 protein expression was negatively correlated with the TRIM16 protein expression levels in breast cancer specimens. Finally, we observed that Gli-1 was a mediator for shTRIM16-induced CSC behavior in breast cancer cells.

In conclusion, our data demonstrated that TRIM16 provides a vital function in inhibiting breast CSCs, via a mechanism that is at least partially controlled by Gli-1. Thus, we propose that the candidate tumor-suppressor gene TRIM16 may be an effective therapeutic target in the future management of breast cancer.

Acknowledgements

The present study was supported by the Scientific and Technological Research Projects of Shaanxi (grant no. 2013K12-12-03).

References